Therapeutic potential of anticancer immunotoxins

被引：65

作者：

Choudhary, Swati ^{[1
]}

Mathew, Mrudula ^{[1
]}

Verma, Rama S. ^{[1
]}

机构：

[1] Indian Inst Technol, Stem Cell & Mol Biol Lab, Dept Biotechnol, Madras 600036, Tamil Nadu, India

来源：

DRUG DISCOVERY TODAY | 2011年 / 16卷 / 11-12期

关键词：

PHASE-I TRIAL; ANTI-MESOTHELIN IMMUNOTOXIN; RECOMBINANT IMMUNOTOXIN; RFB4(DSFV)-PE38 BL22; CYTOTOXIC ACTIVITY; DENILEUKIN DIFTITOX; ANTITUMOR-ACTIVITY; REDUCED IMMUNOGENICITY; COMPLETE REGRESSION; CLINICAL-EVALUATION;

D O I：

10.1016/j.drudis.2011.04.003

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Immunotoxins are chimeric proteins consisting of a tumor-specific ligand (antibody, growth factor or peptide) linked to a modified toxin. These molecules bind to cell surface receptors and are subsequently internalized by endocytosis, resulting in cell death. Advances in protein engineering and phage display have enabled the selection of high-affinity targeting moieties. Denileukin diftitox is the only FDA-approved immunotoxin, although others such as BL22 are currently in different phases of development. This review elaborates the key findings of the important clinical studies relating to various chimeric toxins.

引用

收藏

页码：495 / 503

页数：9

相关论文

共 70 条

[1]

Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2 [J].

Azemar, M ;

Djahansouzi, S ;

Jäger, E ;

Solbach, C ;

Schmidt, M ;

Maurer, AB ;

Mross, K ;

Unger, C ;

von Minckwitz, G ;

Dall, P ;

Groner, B ;

Wels, WS .

BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 (03) :155-164

[2]

SINGLE-CHAIN ANTIGEN-BINDING PROTEINS [J].

BIRD, RE ;

HARDMAN, KD ;

JACOBSON, JW ;

JOHNSON, S ;

KAUFMAN, BM ;

LEE, SM ;

LEE, T ;

POPE, SH ;

RIORDAN, GS ;

WHITLOW, M .

SCIENCE, 1988, 242 (4877) :423-426

[3]

The contributions of Paul Ehrlich to pharmacology: A tribute on the occasion of the centenary of his Nobel Prize [J].

Bosch, Felix ;

Rosich, Laia .

PHARMACOLOGY, 2008, 82 (03) :171-179

[4]

BUDEL LM, 1989, BLOOD, V74, P565

[5]

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers [J].

Chang, K ;

Pastan, I .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (01) :136-140

[6]

A RECOMBINANT IMMUNOTOXIN CONSISTING OF 2 ANTIBODY VARIABLE DOMAINS FUSED TO PSEUDOMONAS EXOTOXIN [J].

CHAUDHARY, VK ;

QUEEN, C ;

JUNGHANS, RP ;

WALDMANN, TA ;

FITZGERALD, DJ ;

PASTAN, I .

NATURE, 1989, 339 (6223) :394-397

[7]

Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity [J].

Chowdhury, PS ;

Viner, JL ;

Beers, R ;

Pastan, I .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :669-674

[8]

Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies [J].

Dean, A. ;

Talpaz, M. ;

Kantarjian, H. ;

Faderl, S. ;

Jabbour, E. ;

Kashani, F. Ravandi ;

O'Brien, S. M. ;

Rosenblum, M. ;

Cortes, J. E. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[9]

Denileukin diftitox: a concise clinical review [J].

Eklund, JW ;

Kuzel, TM .

EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (01) :33-38

[10]

Clinical experience with denileukin diftitox (ONTAK) [J].

Foss, F .

SEMINARS IN ONCOLOGY, 2006, 33 (01) :S11-S16

← 1 2 3 4 5 6 7 →